The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Regulatory News (VRS)

Share Price Information for Versarien (VRS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.1005
Bid: 0.10
Ask: 0.1045
Change: 0.00 (0.00%)
Spread: 0.0045 (4.50%)
Open: 0.1005
High: 0.00
Low: 0.00
Prev. Close: 0.1005
VRS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

30 Oct 2023 11:52

RNS Number : 7331R
Versarien PLC
30 October 2023
 

30 October 2023

Versarien Plc

("Versarien" or the "Company")

Result of General Meeting

Versarien Plc (AIM: VRS), the advanced materials engineering group, is pleased to confirm that at the Company's General Meeting held earlier today, all resolutions were duly passed. Full details of the resolutions are set out in the Notice of General Meeting dated 12 October 2023 and available on the Company's website at: https://www.versarien.com/investors/reports-and-presentations/

The proxy votes cast were as follows:

Resolution

For

 

Against

 

Abstain

1 - to sub-divide the Existing Ordinary Shares into New Ordinary Shares and Deferred Shares

 

23,267,848

96.07%

951,505

3.93%

645,931

2 - to alter the Articles to allow for the issue of New Deferred Shares

 

23,260,834

95.77%

1,027,547

4.23%

576,903

3 - to authorise the Directors to allot shares in the Company

 

22,845,045

95.73%

1,019,150

4.27%

1,001,089

4 - to disapply statutory pre-emption rights

 

22,609,443

94.75%

1,253,097

5.25%

1,002,744

 

Share Capital Reorganisation

Following the passing of the resolutions at the General Meeting, each of the Company's 330,779,690 Existing Ordinary Shares will be sub-divided into one New Ordinary Share of 0.1p (the "New Ordinary Shares") and one deferred share of 0.9p ("New Deferred Shares"). The New Deferred Shares will have little economic value as they will not carry any rights to vote or dividend rights, although the New Deferred Shares will rank pari passu with the New Ordinary Shares on a return of capital or on a winding up of the Company.

 

Admission to AIM and Total Voting Rights

Dealings on AIM in the Existing Ordinary Shares is expected to cease at the close of business on 30 October 2023. Application has been made for the admission of 330,779,690 New Ordinary Shares to trading on AIM ("Admission") and it is expected that Admission will take place and that trading in the New Ordinary Shares will commence at 8.00 a.m. on or around 31 October 2023. No application will be made for admission of the New Deferred Shares to trading on AIM nor will any such application be made to any other exchange.

Following Admission, there will be a total of 330,779,690 New Ordinary Shares, with voting rights, in issue. The Company does not hold any shares in treasury. Consequently, 330,779,690 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise indicated, all defined terms in this announcement shall have the same meaning as described in the Company's announcement dated 12 October 2023 and the Circular which was posted to shareholders on the same day.

 

 

For further information please contact:

 

Versarien

Stephen Hodge, Chief Executive Officer

Chris Leigh, Chief Financial Officer

c/o IFC

SP Angel Corporate Finance (Nominated Adviser and Broker)

Matthew Johnson, Adam Cowl

+44 (0)20 3470 0470

 

 

IFC Advisory Limited (Financial PR and Investor Relations)

Tim Metcalfe, Zach Cohen

+44 (0) 20 3934 6630

 

For further information please see: http://www.versarien.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMWPGGAUUPWGGU
Date   Source Headline
3rd Nov 20174:40 pmRNSTrading Update and Notice of Results
31st Oct 20174:40 pmRNSSecond Price Monitoring Extn
31st Oct 20174:35 pmRNSPrice Monitoring Extension
31st Oct 20172:05 pmRNSSecond Price Monitoring Extn
31st Oct 20172:00 pmRNSPrice Monitoring Extension
31st Oct 20177:00 amRNSCollaboration with Israel Aerospace Industries
2nd Oct 20177:00 amRNSAward of Share Options to Directors
22nd Sep 20171:11 pmRNSDirector/PDMR Shareholding
21st Sep 20179:38 amRNSHolding(s) in Company
20th Sep 20179:00 amRNSHolding(s) in Company
19th Sep 201711:01 amRNSHolding(s) in Company
19th Sep 201711:00 amRNSHolding(s) in Company
19th Sep 20177:00 amRNSSignificant Tender Win
14th Sep 20176:03 pmRNSHolding(s) in Company
13th Sep 201711:45 amRNSResult of AGM
12th Sep 201712:26 pmRNSHolding(s) in Company
12th Sep 20177:00 amRNSHolding(s) in Company
11th Sep 20178:09 amRNSHolding(s) in Company
7th Sep 20177:00 amRNSContract Win
1st Sep 20177:00 amRNSHolding(s) in Company
23rd Aug 20173:45 pmRNSHolding(s) in Company
9th Aug 201710:30 amRNSNotice of AGM
3rd Jul 20177:00 amRNSFinal Results for the year ended 31 March 2017
20th Apr 20177:00 amRNSInvestor Event
20th Apr 20177:00 amRNSResignation of Director
6th Apr 201711:13 amRNSHolding(s) in Company
4th Apr 20173:45 pmRNSHolding(s) in Company
4th Apr 20178:00 amRNSHolding(s) in Company
21st Mar 20177:00 amRNSCambridge Graphene Update
15th Mar 20179:43 amRNSHolding(s) in Company
9th Mar 20171:00 pmRNSHolding(s) in Company
6th Mar 20177:00 amRNSSuccessful Fundraising of £1.5 million
3rd Mar 20174:38 pmRNSFundraising of approximately £1 million
16th Feb 20177:00 amRNSNanene Distribution Agreement
8th Feb 20177:00 amRNSLaunch of Nanene
30th Jan 201710:04 amRNSHolding(s) in Company
19th Jan 20171:21 pmRNSAcquisition and Trading Update
19th Dec 20167:00 amRNSFurther Graphene Enhanced PAEK Plastics Agreement
14th Dec 201610:45 amRNSHolding(s) in Company
14th Dec 20167:00 amRNSGraphene enhanced PAEK Thermoplastics Agreement
29th Nov 20167:01 amRNSInterim Results
29th Nov 20167:00 amRNSSignificant Graphene Order
23rd Nov 20167:00 amRNSNotice of Results
9th Nov 201610:00 amRNSInvestor site visit presentations
31st Oct 20169:15 amRNSDebt for Equity Swap with UoM
27th Oct 20167:00 amRNSNew Healthcare Graphene Project
18th Oct 20167:00 amRNSInvestor Event
13th Oct 20167:00 amRNSCompletion of NGI composite project
3rd Oct 20167:00 amRNSAcquisition of AAC Cyroma
27th Sep 20161:38 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.